Even without formal trial data on sequencing, clinicians are beginning to prescribe one oral SERD after progression on another (e.g., vepdegestrant after imlunestrant). This practice is driven by a belief in targeting the driving ESR1 mutation and by patient-specific factors like toxicity aversion, highlighting a real-world clinical need.

Due to fedratinib's significant GI side effect profile and the logistical difficulty of measuring thiamine levels, clinicians should proactively provide patients with thiamine supplements, anti-emetics, and anti-diarrheal therapies. Instructing patients to take the drug with food can also help mitigate GI toxicity.

The Lidara study showed SERD benefit in patients without pre-existing ESR1 mutations. Success is likely multifactorial: SERDs are more effective and better tolerated than AIs. Critically, they also prevent the most common resistance mechanism—the acquisition of ESR1 mutations—from developing in the first place, altering the disease's future trajectory.

A subtle but significant quality-of-life benefit of oral SERDs over AIs is their mechanism allows for the safe use of topical vaginal estrogens. This is a major advantage for younger patients who struggle with genitourinary symptoms but cannot use estrogens with AIs due to the risk of systemic absorption and spillover effects.

Comparing elacestrant (EMERALD) and imlunestrant (EMBER-3) is flawed because the patient populations were fundamentally different. EMERALD's patients were more heavily pretreated, a fact starkly illustrated by the standard-of-care arms' median Progression-Free Survival of 1.9 months versus 3.8 months in EMBER-3.

With multiple FDA-approved oral SERDs available, clinical decision-making is heavily influenced by their distinct side effect profiles. Elacestrant predominantly causes nausea, while iminoralestrant causes diarrhea. This distinction is a primary factor in tailoring treatment to individual patients.

Unlike earlier endocrine therapies, investigational oral SERDs like camisestrant and giridescent can cause unusual adverse events. These include sinus bradycardia (requiring ECG monitoring) and photopsia (transient flashes of light), which clinicians and nurses must be aware of for patient education and management.

A significant, immediate use for adjuvant oral SERDs like gerodestrant will be for patients who cannot tolerate the arthralgias and other side effects of standard aromatase inhibitors (AIs). This addresses a large and challenging clinical problem, positioning SERDs as a key alternative for maintaining long-term adherence to endocrine therapy.

Unlike some endocrine therapies, oral SERDs used in premenopausal women require concurrent ovarian suppression (e.g., with a GnRH agonist). This is a critical safety measure to mitigate the risk of developing ovarian cysts, a potential side effect of using these agents without adequately suppressing ovarian function.